139 related articles for article (PubMed ID: 28829952)
1. Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir.
Mohideen M; Quijano E; Song E; Deng Y; Panse G; Zhang W; Clark MR; Saltzman WM
Biomaterials; 2017 Nov; 144():144-154. PubMed ID: 28829952
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-releasing nanofiber composites for enhanced in vivo vaginal retention.
Krogstad EA; Ramanathan R; Nhan C; Kraft JC; Blakney AK; Cao S; Ho RJY; Woodrow KA
Biomaterials; 2017 Nov; 144():1-16. PubMed ID: 28802690
[TBL] [Abstract][Full Text] [Related]
3. Investigation of the physicochemical and physicomechanical properties of a novel intravaginal bioadhesive polymeric device in the pig model.
Ndesendo VM; Pillay V; Choonara YE; du Toit LC; Buchmann E; Meyer LC; Khan RA; Rosin U
AAPS PharmSciTech; 2010 Jun; 11(2):793-808. PubMed ID: 20446071
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-mediated drug delivery to treat infections in the female reproductive tract: evaluation of experimental systems and the potential for mathematical modeling.
Sims LB; Frieboes HB; Steinbach-Rankins JM
Int J Nanomedicine; 2018; 13():2709-2727. PubMed ID: 29760551
[TBL] [Abstract][Full Text] [Related]
5. Novel approach for enhancing skin allograft survival by bioadhesive nanoparticles loaded with rapamycin.
Liu Y; Ouyang Y; Yu L; Wang P; Peng Z; Liu H; Zhao S; Wang H; Zhou Z; Deng Y; Liu Y; Xie J
Int J Pharm; 2024 Feb; 651():123742. PubMed ID: 38151102
[TBL] [Abstract][Full Text] [Related]
6. Miniaturized Polymeric Systems for the Intravaginal Gene Therapies: Recent Update on Unconventional Delivery.
Pandey M; Ting JSS; Gorain B; Jain N; Mayuren J
Curr Pharm Des; 2023; 29(40):3254-3262. PubMed ID: 37438899
[TBL] [Abstract][Full Text] [Related]
7. Biodegradable bioadhesive nanoparticle incorporation of broad-spectrum organic sunscreen agents.
Suh HW; Lewis J; Fong L; Ramseier JY; Carlson K; Peng ZH; Yin ES; Saltzman WM; Girardi M
Bioeng Transl Med; 2019 Jan; 4(1):129-140. PubMed ID: 30680324
[TBL] [Abstract][Full Text] [Related]
8. In vitro and ex vivo models for evaluating vaginal drug delivery systems.
Shapiro RL; DeLong K; Zulfiqar F; Carter D; Better M; Ensign LM
Adv Drug Deliv Rev; 2022 Dec; 191():114543. PubMed ID: 36208729
[TBL] [Abstract][Full Text] [Related]
9. Verteporfin-Loaded Bioadhesive Nanoparticles for the Prevention of Hypertrophic Scar.
Wang P; Peng Z; Yu L; Liu Y; Wang H; Zhou Z; Liu H; Hong S; Nie Y; Deng Y; Liu Y; Xie J
Small Methods; 2023 Dec; ():e2301295. PubMed ID: 38084464
[TBL] [Abstract][Full Text] [Related]
10. Formulation, In Vitro and In Vivo Pharmacokinetics of Anti-HIV Vaginal Bioadhesive Gel.
Chatterjee A; Bhowmik BB; Thakur YS
J Young Pharm; 2011 Apr; 3(2):83-9. PubMed ID: 21731351
[TBL] [Abstract][Full Text] [Related]
11. Composite thermoresponsive hydrogel with auranofin-loaded nanoparticles for topical treatment of vaginal trichomonad infection.
Zhang Y; Miyamoto Y; Ihara S; Yang JZ; Zuill DE; Angsantikul P; Zhang Q; Gao W; Zhang L; Eckmann L
Adv Ther (Weinh); 2019 Dec; 2(12):. PubMed ID: 32377561
[No Abstract] [Full Text] [Related]
12. A Single-Center Retrospective Cohort Analysis of Maternal and Infant Outcomes in HIV-Infected Mothers Treated with Integrase Inhibitors During Pregnancy.
Mounce ML; Pontiggia L; Adams JL
Infect Dis Ther; 2017 Dec; 6(4):531-544. PubMed ID: 28905222
[TBL] [Abstract][Full Text] [Related]
13. Reversal of tenofovir induced nephrotoxicity: case reports of two patients.
Some F; Koech M; Chesire E; Kigen G
Pan Afr Med J; 2017; 27():126. PubMed ID: 28904656
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir alafenamide nephrotoxicity in an HIV-positive patient: A case report.
Novick TK; Choi MJ; Rosenberg AZ; McMahon BA; Fine D; Atta MG
Medicine (Baltimore); 2017 Sep; 96(36):e8046. PubMed ID: 28885375
[TBL] [Abstract][Full Text] [Related]
15. Recognition of possible risk factors for clinically significant drug-drug interactions among Indian people living with HIV receiving highly active antiretroviral therapy and concomitant medications.
Priyanka PSSL; Varma DM; Immadisetti K; Rajesh R; Vidyasagar S; Guddattu V
Int J Risk Saf Med; 2017; 29(1-2):25-55. PubMed ID: 28885219
[TBL] [Abstract][Full Text] [Related]
16. Primary HIV Infection: Clinical Presentation, Testing, and Treatment.
Henn A; Flateau C; Gallien S
Curr Infect Dis Rep; 2017 Sep; 19(10):37. PubMed ID: 28884279
[TBL] [Abstract][Full Text] [Related]
17. B-type natriuretic peptide and renal function in Japanese patients with type 2 diabetes mellitus: The Dogo Study.
Furukawa S; Sakai T; Niiya T; Miyaoka H; Miyake T; Yamamoto S; Tanaka K; Ueda T; Senba H; Torisu M; Minami H; Matsuura B; Hiasa Y; Miyake Y
Endocr J; 2017 Dec; 64(12):1131-1136. PubMed ID: 28855437
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 27 acts as a predictor of prognosis in chronic heart failure patients.
Traxler D; Lainscak M; Simader E; Ankersmit HJ; Jug B
Clin Chim Acta; 2017 Oct; 473():127-132. PubMed ID: 28844461
[TBL] [Abstract][Full Text] [Related]
19. Assessment of renal function in routine care of people living with HIV on ART in a resource-limited setting in urban Zambia.
Deckert A; Neuhann F; Klose C; Bruckner T; Beiersmann C; Haloka J; Nsofwa M; Banda G; Brune M; Reutter H; Rothenbacher D; Zeier M
PLoS One; 2017; 12(9):e0184766. PubMed ID: 28931037
[TBL] [Abstract][Full Text] [Related]
20. Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction.
Thawabi M; Hawatmeh A; Studyvin S; Habib H; Shamoon F; Cohen M
Cardiovasc Diagn Ther; 2017 Aug; 7(4):359-366. PubMed ID: 28890872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
